16:18 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers showing that lymphoma, inflammation and cardiovascular disease candidate KAND567 (AZD8797) was well tolerated. The double-blind, placebo-controlled trial evaluated single doses of up...